Apollo Endosurgery Inc Kapitalrendite
Was ist das Kapitalrendite von Apollo Endosurgery Inc?
Kapitalrendite von Apollo Endosurgery Inc ist -89.48%
Was ist die Definition von Kapitalrendite?
Die Eigenkapitalrendite ist ein Maß für die Rentabilität eines Unternehmens im Verhältnis zum Buchwert des Eigenkapitals. Sie wird berechnet, indem das Nettoergebnis des Geschäftsjahres durch das gesamte Eigenkapital geteilt wird.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Kapitalrendite von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Apollo Endosurgery Inc
Was macht Apollo Endosurgery Inc?
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the X-Tack™ Endoscopic HeliX Tacking System, the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Unternehmen mit kapitalrendite ähnlich Apollo Endosurgery Inc
- Guangdong Tannery hat Kapitalrendite von -89.80%
- Kin Mining NL hat Kapitalrendite von -89.76%
- MultiPlan hat Kapitalrendite von -89.59%
- Prodigy Ventures hat Kapitalrendite von -89.51%
- 4D pharma plc hat Kapitalrendite von -89.48%
- 4D pharma plc hat Kapitalrendite von -89.48%
- Apollo Endosurgery Inc hat Kapitalrendite von -89.48%
- Teladoc Health hat Kapitalrendite von -89.48%
- Padmanabh Industries hat Kapitalrendite von -89.33%
- Vy Global Growth hat Kapitalrendite von -89.30%
- Nickel Rock Resources hat Kapitalrendite von -89.24%
- engage:BDR hat Kapitalrendite von -89.19%
- IR Resources hat Kapitalrendite von -89.12%